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Results of association analysis for patient's background and SJS/TEN with severe
ocular involvements.
Category Factors Mild Severe Severe/Total (%) Fisher's exact test
(p value)
Sex Male 73 27 27.0 0.22
Female 62 35 36.1
Age 60 79 28 26.2 0.09Dear Editor,
StevenseJohnson syndrome (SJS) and toxic epidermal necrolysis
(TEN) are severe cutaneous adverse drug reactions often affecting
mucosal tissues such as ocular surface, oral cavity, and genitals.1,2
The severe ocular surface disorders include pseudomembrane for-
mation and epithelial erosion in the acute phase, often leading to
permanent impairment or loss of vision.3
We recruited Japanese patients with SJS/TEN through partici-
pating universities and hospitals and via the nationwide case
collection network from June 2006 to June 2013.4,5 The study was
approved by the institutional review boards of all participating in-
stitutions, and written informed consent was obtained from all the
patients (patient anonymity was preserved using the approved
methods). Clinical information such as patients' background, pri-
mary (underlying) disease, symptoms, and administered drugs
before the onset of SJS/TEN was also collected. Two experts diag-
nosed the disease using a standardized case report form, containing
the criteria proposed by Bastuji-Garin et al.6 except that the
SJSeTEN overlap was categorized as TEN according to the severity
criteria currently used in Japan.7 Drugs that were administered
continuously to the patients from 1 day to 2 months before the
onset of SJS/TEN were assumed to be the causative agents.
According to the clinical information, the ocular surface involve-
ments were graded as follows: 0, no symptoms; 1, only hyperemia
of the bulbar and palpebral conjunctiva; 2, either pseudomembrane
formation or a defect/erosion of the conjunctiva/corneal epithelia;
and 3, both pseudomembrane formation and a defect/erosion of the
conjunctiva/corneal epithelia. Grades 0/1 and 2/3 were grouped as
mild and severe ocular surface involvements, respectively.
A total of 197 patients with SJS/TEN (97 females, mean age
56.6 ± 22.3 years) were enrolled. The number of probable SJS, SJS,
and TEN cases was 23, 115, and 59, respectively. The frequency of
severe ocular surface involvement tended to be higher among fe-
male and patients younger than 60 years but was not statistically
signiﬁcant (Table 1).
The frequencies of mild and severe ocular surface involvements
caused by the drug or the drug group, the number of which was
more than 14, were statistically evaluated by Fisher's exact proba-
bility test using JMP ver. 7.0.1 (SAS Institute Japan, Tokyo, Japan).
As shown in Table 2, patients with SJS/TEN who were treated
with cephalosporins or loxoprofen exhibited relatively higher ten-
dencies of experiencing severe ocular surface involvements, but the
difference was marginal (0.05 < p < 0.07). No differences werePeer review under responsibility of Japanese Society of Allergology.
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licenses/by-nc-nd/4.0/).observed in the rates of experiencing severe ocular surface involve-
ments in patients with SJS/TEN that is associated with other drugs
such as carbamazepine, allopurinol, and quinolones.
On the other hand, we found that patients with SJS/TEN associ-
ated with acetaminophen showed a signiﬁcantly higher rate
(55.6%) of experiencing severe ocular surface involvements than
those not treated with acetaminophen (27.6%) (p < 0.01). Among
27 acetaminophen-administered patients, 16 patients had been
diagnosed by DLST, and 10 (62.5%) of them were positive. In the
SJS group, the rate of acetaminophen-associated severe ocular in-
volvements (7/36 patients, 19.4%) was signiﬁcantly higher than
those with mild involvements (4/79, 5.1%) (p ¼ 0.034, data not
shown) while there was no signiﬁcant association in the case of
TEN group, although the skin reaction of TEN is more severe than
SJS. These results suggest that the ocular surface would be severely
damaged by acetaminophen more frequently than by the other
drugs in SJS patients. When acetaminophen and non-steroidal
anti-inﬂammatory drugs (NSAIDs) were combined as an antipyre-
ticeanalgesic (AA) group, the signiﬁcance was lost (p ¼ 0.26).
We divided these AA-associated patients with SJS/TEN into two
groups: one group comprised patients taking drugs for common
cold and the other comprised patients taking such drugs for condi-
tions other than common cold, before the onset of SJS/TEN. We
found that the patients taking these drugs for common cold expe-
rienced severe ocular surface involvements at a signiﬁcantly higher
rate (65.4%) than those taking these drugs for conditions other than
common cold, such as rheumatoid arthritis (19.5%) (p < 0.001). The
samewas true in the case of acetaminophen (p < 0.01). Drugs other
than AAs did not show such a tendency (p > 0.05, data not shown).
In a previous study by the EuroSCAR group, despite the high
relative risk, acetaminophen was regarded as a confounding factor
for the assessment of the risk of SJS/TEN because it was often
administered concomitantly with other “highly suspected” drugs
such as allopurinol and carbamazepine.8 In the present study,<60 56 34 37.8
Number of Japanese SJS/TEN patients with mild/severe ocular involvements and the
frequencies of severe cases are shown.
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Table 2
Drugs/drug groups and frequencies of ocular surface involvements in Japanese SJS/TEN patients.




Mild Severe Severe/Total (%) Mild Severe Severe/Total (%)
All patients 135 62 31.5
Aromatic anti-epileptics (AAE)
All of AAE 35 17 32.7 100 45 31.0 0.86
Carbamazepine 11 5 31.3 124 57 31.5 1.00
Lamotrigine 9 7 43.8 126 55 30.4 0.27
Anti-hyperuricemia
Allopurinol 16 10 38.5 119 52 30.4 0.50
Antibacterial drug
Quinolones 15 7 31.8 120 55 31.4 1.00
Proton pump inhibitors 12 3 20.0 123 59 32.4 0.40
Antibiotics
All of antibiotics 30 18 37.5 105 44 29.5 0.26
Cephalosporins 11 11 50.0 124 51 29.1 0.05 2.43 (0.99/5.97)
Antipyretic analgesics (AAs)
All of AAs 42 25 37.3 93 37 28.5 0.26
Aspirin 8 7 46.7 127 55 30.2 0.25
Loxoprofen 13 12 48.0 122 50 29.1 0.07 2.25 (0.96/5.28)
Acetaminophen 12 15 55.6 123 47 27.6 0.0065 3.27 (1.43/7.50)
Patients receiving AAs for treatment of coldy 9 17 65.4
0.0002 7.79 (2.55/23.8)
Patients receiving AAs for treatment of other diseases 33 8 19.5
Acetaminophen for treatment of coldy 4 13 76.5
0.0069 13.0 (1.92/88.0)
Acetaminophen for treatment of other diseases 8 2 20.0
Japanese SJS/TEN patients were categorized by culprit drugs/drug groups.
y Judged according to primary (underlying) disease in the ﬁlled case report forms (e.g. common cold, acute upper respiratory inﬂammation, and acute adenoiditis) and/or
drug name (e.g. multi-ingredient cold remedy). Mycoplasma pneumoniae or inﬂuenza were excluded from this category.
g These authors contributed equally to this work.
Letter to the Editor / Allergology International 64 (2015) 379e381380however, 14 of 15 patients with acetaminophen-associated SJS/TEN
and severe ocular surface involvement had not taken such drugs
together. Therefore, at least among Japanese patients with SJS/
TEN with severe ocular surface involvements, acetaminophen is
strongly suspected to be a causative drug, particularly when this
drug was taken for the treatment of common cold.
In conclusion, we found that 1) patients with SJS/TEN taking
acetaminophen showed a signiﬁcantly higher rate of experiencing
severe ocular surface involvements than those taking other SJS/
TEN frequently causative drugs such as carbamazepine, allopurinol,
and quinolones; 2) the patients taking AAs, including acetamino-
phen and/or NSAIDs, for the treatment of common cold showed a
high frequency of patients with SJS/TEN experiencing severe ocular
surface involvements compared with those taking AAs for the
treatment of other diseases. These results suggest that not only
AAs including cold medicine but also viral infections causing
cold-like symptoms play some important roles in the development
of severe ocular surface involvements. Note that our recent study
showed that cold medicine-associated patients with SJS/TEN with
severe ocular complications are associated with certain types of
HLA (HLA-A*02:06 and HLA-A*44:03)9 and/or IKZF1.10 Taken
together, these results suggest the existence of unknown unique
mechanisms underlying the development of ocular disorders in
SJS/TEN caused by AAs. The patients with SJS/TEN taking these
drugs for common cold should be taken special care of their eyes
and the skin to prevent severe ocular sequelae.
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